Found: 7
Select item for more details and to access through your institution.
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 4, p. 442, doi. 10.1002/cpdd.1056
- By:
- Publication type:
- Article
Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 1, p. 8, doi. 10.1002/cpdd.878
- By:
- Publication type:
- Article
Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 956, doi. 10.1002/cpdd.1308
- By:
- Publication type:
- Article
Use of Bicycle Exercise Echocardiography for Unexplained Exertional Dyspnea.
- Published in:
- Clinical Cardiology, 2009, v. 32, n. 6, p. 302, doi. 10.1002/clc.20593
- By:
- Publication type:
- Article
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long-Term Warfarin Therapy.
- Published in:
- Pharmacotherapy, 2007, v. 27, n. 5, p. 691, doi. 10.1592/phco.27.5.691
- By:
- Publication type:
- Article
Characteristics of Exercise-Induced Intrapulmonary Arteriovenous Fistula in Patients with Unexplained Exertional Dyspnea.
- Published in:
- Echocardiography, 2010, v. 27, n. 8, p. 908, doi. 10.1111/j.1540-8175.2010.01168.x
- By:
- Publication type:
- Article
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 2, p. 242, doi. 10.1002/art.42391
- By:
- Publication type:
- Article